{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T16:12:53Z","timestamp":1778343173835,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.cca.2019.10.002","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T13:01:26Z","timestamp":1571144486000},"page":"42-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Diagnostic performance of HE4 and ROMA among Chinese women"],"prefix":"10.1016","volume":"500","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7334-6334","authenticated-orcid":false,"given":"Yuhuan","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2019.10.002_b0005","doi-asserted-by":"crossref","unstructured":"R. Siegel, D. Naishadham, A. Jemal, Cancer statistics, 2013, CA: a cancer journal for clinicians 63(1) (2013) 11\u201330.","DOI":"10.3322\/caac.21166"},{"key":"10.1016\/j.cca.2019.10.002_b0010","doi-asserted-by":"crossref","unstructured":"R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2017, CA: a cancer journal for clinicians 67(1) (2017) 7\u201330.","DOI":"10.3322\/caac.21387"},{"issue":"4","key":"10.1016\/j.cca.2019.10.002_b0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","article-title":"Progress and challenges in screening for early detection of ovarian cancer","volume":"3","author":"Jacobs","year":"2004","journal-title":"Mol. Cell. Proteom. : MCP"},{"issue":"6","key":"10.1016\/j.cca.2019.10.002_b0020","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/01.AOG.0000220516.34053.48","article-title":"Diagnosis and management of epithelial ovarian cancer","volume":"107","author":"Bhoola","year":"2006","journal-title":"Obstet. Gynecol."},{"issue":"9","key":"10.1016\/j.cca.2019.10.002_b0025","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(07)70245-0","article-title":"Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995\u201399: results of the EUROCARE-4 study","volume":"8","author":"Berrino","year":"2007","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.cca.2019.10.002_b0030","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/ijgc-00009577-200509000-00001","article-title":"CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use","volume":"15","author":"Duffy","year":"2005","journal-title":"Int. J. Gynecol. Can.: Off. J. Int. Gynecol. Can. Soc."},{"issue":"2","key":"10.1016\/j.cca.2019.10.002_b0035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ygyno.2009.09.041","article-title":"Current state of biomarker development for clinical application in epithelial ovarian cancer","volume":"116","author":"Moore","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.cca.2019.10.002_b0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2005.06.040","article-title":"Potential markers that complement expression of CA125 in epithelial ovarian cancer","volume":"99","author":"Rosen","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.cca.2019.10.002_b0045","doi-asserted-by":"crossref","unstructured":"C.M. Sturgeon, M.J. Duffy, U.H. Stenman, H. Lilja, N. Brunner, D.W. Chan, R. Babaian, R.C. Bast, Jr., B. Dowell, F.J. Esteva, C. Haglund, N. Harbeck, D.F. Hayes, M. Holten-Andersen, G.G. Klee, R. Lamerz, L.H. Looijenga, R. Molina, H.J. Nielsen, H. Rittenhouse, A. Semjonow, M. Shih Ie, P. Sibley, G. Soletormos, C. Stephan, L. Sokoll, B.R. Hoffman, E.P. Diamandis, B. National Academy of Clinical, National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers, Clin. Chem. 54(12) (2008) e11\u201379.","DOI":"10.1373\/clinchem.2008.105601"},{"issue":"6","key":"10.1016\/j.cca.2019.10.002_b0050","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s13277-011-0204-3","article-title":"HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases","volume":"32","author":"Molina","year":"2011","journal-title":"Tumour Biol.: J. Int. Soc. Oncodev. Biol. Med."},{"issue":"1","key":"10.1016\/j.cca.2019.10.002_b0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.cca.2019.10.002_b0060","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.cca.2019.10.002_b0065","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0028-2243(85)90130-3","article-title":"Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma","volume":"19","author":"Bast","year":"1985","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"8","key":"10.1016\/j.cca.2019.10.002_b0070","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/37.8.1379","article-title":"Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases","volume":"37","author":"Molina","year":"1991","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.cca.2019.10.002_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.05.017","article-title":"Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women","volume":"205","author":"Holcomb","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.cca.2019.10.002_b0080","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ijc.26129","article-title":"Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer","volume":"130","author":"Park","year":"2012","journal-title":"Int. J. Can. J. Int. du cancer"},{"issue":"13","key":"10.1016\/j.cca.2019.10.002_b0085","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstrom","year":"2003","journal-title":"Can. Res."},{"issue":"15\u201316","key":"10.1016\/j.cca.2019.10.002_b0090","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cca.2011.04.028","article-title":"HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm","volume":"412","author":"Ruggeri","year":"2011","journal-title":"Clinica chimica acta; Int. J. Clin. Chem."},{"issue":"6","key":"10.1016\/j.cca.2019.10.002_b0095","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erm.09.39","article-title":"HE4 as a biomarker for ovarian and endometrial cancer management","volume":"9","author":"Li","year":"2009","journal-title":"Expert Rev. Mol. Diagnost."},{"issue":"5","key":"10.1016\/j.cca.2019.10.002_b0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcla.20340","article-title":"The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass","volume":"23","author":"Montagnana","year":"2009","journal-title":"J. Clin. Lab. Anal."},{"issue":"3","key":"10.1016\/j.cca.2019.10.002_b0105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2011.02.022","article-title":"No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting","volume":"121","author":"Jacob","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.cca.2019.10.002_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.cca.2019.10.002_b0115","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","article-title":"HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm","volume":"104","author":"Van Gorp","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.cca.2019.10.002_b0120","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/CCLM.2011.075","article-title":"The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?","volume":"49","author":"Montagnana","year":"2011","journal-title":"Clin. Chem. Lab. Med.: CCLM\/FESCC"},{"issue":"3","key":"10.1016\/j.cca.2019.10.002_b0125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1515\/CCLM.2011.085","article-title":"Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population","volume":"49","author":"Kim","year":"2011","journal-title":"Clin. Chem. Laborat. Med.: CCLM\/FESCC"},{"issue":"2","key":"10.1016\/j.cca.2019.10.002_b0130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol.: J. Int. Soc. Oncodevelopmental Biol. Med."},{"issue":"3","key":"10.1016\/j.cca.2019.10.002_b0135","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","article-title":"Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass","volume":"117","author":"Nolen","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.cca.2019.10.002_b0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-0-387-68969-2_2","article-title":"SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and\/or each other","volume":"622","author":"Hellstrom","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.cca.2019.10.002_b0145","doi-asserted-by":"crossref","unstructured":"G.H.H. G, Youden's index and the weight of evidence, Methods of information in medicine (2) (2015) 198\u20139.","DOI":"10.3414\/ME14-04-0003"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119320650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119320650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:50:08Z","timestamp":1757861408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898119320650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":29,"alternative-id":["S0009898119320650"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2019.10.002","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic performance of HE4 and ROMA among Chinese women","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2019.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}